The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADVFN Regulatory News (AFN)

Share Price Information for ADVFN (AFN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.50
Bid: 10.00
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.00 (10.00%)
Open: 10.50
High: 10.50
Low: 10.50
Prev. Close: 10.50
AFN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

25 Mar 2015 17:09

RNS Number : 4829I
ADVFN PLC
25 March 2015
 



25 March 2015

 

ADVFN PLC

 

("ADVFN" or the "Company")

 

Unaudited Interim Results for the Six Months Ended 31 December 2014

 

 

ADVFN today announces its unaudited interim results for the six months ended 31 December 2014.

 

Chief Executive's Statement

 

I am pleased to announce a solid start to the new financial year with sales up 7.8 per cent. from £4.46 million to £4.8 million from the same period a year ago. Our cash position has also increased slightly compared to the same period last year. 

While sales growth has been good, we have won these gains against a background of markets which have ebbed and flowed. This result has therefore come from developments from the broad spread of our offerings, where successes compensate for any downward drift elsewhere.

Our growing newsletter business and new products in the US have been a highlight and we feel these offer strong potential for growth going forward as we roll them out into new territories.

These factors represent a broadening of our revenue potential across our markets as we develop our offerings to reach these wider audiences.

We haven't suffered any disasters or witnessed any miracles in this half year but this period has represented a period of consistent progress as we continue to build on the ADVFN and Investorshub platform.

While doing so, we have re-organised our share capital and completed a US OTC QX market listing with an eye to exposing our huge US audience to the possibility of become shareholders in our company through US listed ADRs. We are hopeful that this will provide a good basis to add to shareholder value in 2015.

Share consolidation

At the Company's General Meeting held on 20 August 2014, the resolution to approve the share consolidation of existing issued Ordinary shares of £0.01 each in the capital of the Company to be consolidated into ordinary shares of £0.25 each ("Ordinary Shares"), was duly passed. The number of post consolidation Ordinary Shares is disclosed above, together with the restated loss per share amounts. In addition, the shares were to be subdivided into 1 ordinary share of par value 1 pence and 1 Deferred share of 24 pence par value; the Deferred shares were then cancelled. Finally, the par value was reduced from 1 pence to 0.2 pence. The number of post consolidation Ordinary Shares is disclosed together with the restated loss per share amounts (see note 3).

Financial performance

 

Key financial performance for the period has been summarised as follows:

 

Six Months ended

Six Months ended

31 December 2014

31 December 2013

£'000

£'000

Turnover

4,807

4,458

Loss for the period

(552)

(226)

Operating Loss

(647)

(342)

Loss per share (see note 3)

(2.19)p

(0.90)p

 

 

 

 

Clem Chambers

CEO

25 March 2015

 

For further information, please contact:

Clem Chambers,

ADVFN PLC CEO

0207 0700 909

 

Salmaan Khawaja

Jen Clarke

Jamie Barklem

Grant Thornton UK LLP (Nominated Adviser)

0207 383 5100

 

Consolidated income statement

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2014

2013

2014

£'000

£'000

£'000

unaudited

unaudited

audited

Notes

restated

Revenue

4,807

4,458

9,702

Cost of sales

(718)

(491)

(1,165)

Gross profit

4,089

3,967

8,537

Share based payment

(18)

(47)

(54)

Amortisation of intangible assets

(326)

(465)

(914)

Other administrative expenses

(4,392)

(3,797)

(8,232)

Total administrative expense

(4,736)

(4,309)

(9,200)

Operating loss

(647)

(342)

(663)

Finance income

57

53

108

Loss before tax

(590)

(289)

(555)

Taxation

38

63

101

Total loss after taxation

(552)

(226)

(454)

Loss for the period

(552)

(226)

(454)

Loss per share

Basic and diluted (pence per share)

3

(2.19)

(0.90)

(1.80)

 

 

 

Consolidated statement of comprehensive income

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2014

2013

2014

£'000

£'000

£'000

unaudited

unaudited

audited

Loss for the period

(552)

(226)

(454)

Other comprehensive income:

Exchange differences on translation of foreign operations

196

(146)

(190)

Deferred tax on translation of foreign held assets

(24)

21

29

Total comprehensive income for the year

(380)

(351)

(615)

 

Consolidated balance sheet

31 Dec

31 Dec

30 June

2014

2013

2014

£'000

£'000

£'000

unaudited

unaudited

audited

Assets

Non-current assets

Property, plant and equipment

89

119

71

Goodwill

793

747

724

Intangible assets

1,289

1,502

1,331

Trade and other receivables

202

540

295

Total non-current assets

2,373

2,908

2,421

Current assets

Trade and other receivables

1,264

1,045

1,122

Current tax recoverable

72

33

60

Cash and cash equivalents

1,510

1,493

1,675

Total current assets

2,846

2,571

2,857

Total assets

5,219

5,479

5,278

Equity and liabilities

Equity

Issued capital

50

6,305

6,305

Share premium

-

8,101

8,102

Merger reserve

-

221

221

Share based payments reserve

18

610

617

Foreign exchange reserve

289

153

117

Retained earnings

2,126

(12,289)

(12,517)

Total equity

2,483

3,101

2,845

Non-current liabilities

Deferred tax

128

185

134

Total non-current liabilities

128

185

134

Current liabilities

Trade and other payables

2,606

2,187

2,268

Current tax

2

6

31

Total current liabilities

2,608

2,193

2,299

Total liabilities

2,736

2,378

2,433

Total equity and liabilities

5,219

5,479

5,278

 

Consolidated statement of changes in equity

 

Share capital

Share premium

Merger reserve

Share based payment reserve

Foreign exchange

Retained earnings

Total equity

£'000

£'000

£'000

£'000

£'000

£'000

£'000

At 1 July 2013

6,291

8,062

221

563

278

(12,063)

3,352

Issue of shares

14

39

-

-

-

-

53

Equity settled share options

-

-

-

47

-

-

47

Transactions with owners

14

39

-

47

-

-

100

Loss for the period after tax

-

-

-

-

-

(226)

(226)

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

-

 

(146)

 

-

 

(146)

Deferred tax on translation of foreign held assets

 

-

 

-

 

-

 

-

 

21

 

-

 

21

Total comprehensive income

-

-

-

-

(125)

(226)

(351)

At 31 December 2013

6,305

8,101

221

610

153

(12,289)

3,101

Issue of shares

-

1

-

-

-

-

1

Equity settled share options

-

-

-

7

-

-

7

Transactions with owners

-

1

-

7

-

-

8

Loss for the period after tax

-

-

-

-

-

(228)

(228)

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

-

 

(44)

 

-

 

(44)

Deferred tax on translation of foreign held assets

 

-

 

-

 

-

 

-

 

8

 

-

 

8

Total comprehensive income

-

-

-

-

(36)

(228)

(264)

At 30 June 2014

6,305

8,102

221

617

117

(12,517)

2,845

Equity settled share options

-

-

-

18

-

-

18

Transactions with owners

-

-

-

18

-

-

18

Loss for the period after tax

-

-

-

-

-

(552)

(552)

Other comprehensive income

Exchange differences on translation of foreign operations

 

-

 

-

 

-

 

-

 

196

 

-

 

196

Deferred tax on translation of foreign held assets

 

-

 

-

 

-

 

-

 

(24)

 

-

 

(24)

Total comprehensive income

-

-

-

-

172

(552)

(380)

Share consolidation

(6,255)

(8,102)

(221)

(617)

-

15,195

-

At 31 December 2014

50

-

-

18

289

2,126

2,483

 

 

Consolidated cash flow statement

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2014

2013

2014

£'000

£'000

£'000

unaudited

unaudited

audited

Cash flows from operating activities

Loss for the period before tax

(590)

(289)

(555)

Finance costs

(57)

(53)

(108)

Depreciation of property, plant and equipment

30

30

47

Amortisation

326

465

914

Impairment of financial assets

-

-

250

Share based payments

18

47

54

Decrease/(increase) in trade and other receivables

8

(122)

(149)

Increase in trade and other payables

338

233

314

Net cash generated by operations

73

311

767

Income tax (paid)/received

(9)

12

(3)

Net cash generated by operating activities

64

323

764

Cash flows from investing activities

Payments for property, plant and equipment

(48)

(179)

(57)

Purchase of intangibles

(284)

(156)

(495)

Net cash used by investing activities

(332)

(335)

(552)

Cash flows from financing activities

Proceeds from issue of equity shares

-

53

-

Net cash generated by financing activities

-

53

-

Net (decrease)/increase in cash and cash equivalents

(268)

41

212

Exchange movements

103

(9)

2

Total (decrease)/increase in cash and cash equivalents

(165)

32

214

Cash and cash equivalents at the start of the period

1,675

1,461

1,461

Cash and cash equivalents at the end of the period

1,510

1,493

1,675

 

 

1. Legal status and activities

 

ADVFN Plc ("the Company") is principally involved in the development and provision of financial information primarily via the internet and the development and exploitation of ancillary internet sites.

The Company is a public limited liability company incorporated and domiciled in England and Wales. The address of its registered office is Suite 27, Essex Technology Centre, The Gables, Fyfield Road, Ongar, Essex, CM5 0GA.

 

The Company is quoted on the London Stock Exchange's AIM market under the ticker "AFN".

 

2. Basis of preparation

 

The unaudited consolidated interim financial information is for the six month period ended 31 December 2014. The financial information does not include all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2014, which were prepared under IFRS as adopted by the European Union (EU).

 

The accounting policies adopted in this report are consistent with those of the annual financial statements for the year to 30 June 2014 as described in those financial statements.

 

The interim financial information has not been audited nor has it been reviewed under ISRE 2410 of the Auditing Practices Board. The financial information presented does not constitute statutory accounts as defined by section 434 of the Companies Act 2006. The Group's statutory accounts for the year to 30 June 2014 have been filed with the Registrar of Companies. The auditors, Grant Thornton UK LLP reported on these accounts and their report was unqualified and did not contain a statement under section 498(2) or Section 498(3) of the Companies Act 2006.

 

The financial statements have been prepared on the going concern basis which assumes the Group will continue in existence for the foreseeable future. At 31 December 2014 the Group's cash balances amounted to £1.5 million and the forecasts indicate that this balance will be broadly maintained and then increase in the remainder of the financial year. Accordingly the directors have prepared these financial statements on the going concern basis.

 

3. Loss per share

 

6 months to

 31 Dec

6 months to

 31 Dec

12 months to

 30 June

2014

2013

2014

£'000

£'000

£'000

Restated

Loss for the year attributable to equity shareholders

(552)

(226)

(454)

Loss per share - basic and diluted

(2.19)

(0.90)

(1.80)

Shares

Shares

Shares

Issued ordinary shares at start of the period

25,220,210

25,164,560

25,164,560

Ordinary shares issued in the period

-

55,650

55,650

Issued ordinary shares at end of the period

25,220,210

25,220,210

25,220,210

Weighted average number of shares in issue for the period

25,220,210

25,219,905

25,219,905

Dilutive effect of options

-

-

-

Weighted average shares for diluted earnings per share

25,220,210

25,219,905

25,219,905

The diluted loss per share does not differ from the basic loss per share as the exercise of share options would have the effect of reducing the loss per share and is therefore not dilutive under the terms of IAS 33.

 

Restatement

The shares in issue for the 6 months to 31 December 2013 have been restated as a result of the share consolidation exercise at 1 new share for 25 old shares. This results in a change of the loss per share. The details of this exercise are given below.

3. Loss per share (continued)

 

Share consolidation

At the company's General Meeting held on 20 August 2014, the resolution to approve the share consolidation of existing issued Ordinary shares of £0.01 each in the capital of the company to be consolidated into Ordinary shares of £0.25 each, was duly passed. The number of post consolidation Ordinary shares is disclosed above together with the restated loss per share amounts. In addition, the shares were to be subdivided into 1 Ordinary share of par value 1p and 1 Deferred share of 24p par value; the Deferred shares were then cancelled. Finally, the par value was reduced from 1p to 0.2p.

 

4. Dividends

The directors do not recommend the payment of a dividend.

 

5. Financial statements

Copies of this statement are being posted to shareholders shortly and will be available from the company's registered office at Suite 27, Essex Technology Centre, The Gables, Fyfield Road, Ongar, Essex, CM5 0GA. Electronic copies of this statement will be available on the Company's website at uk.advfn.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR GMGZFNKKGKZM
Date   Source Headline
21st Mar 20249:49 amRNSHalf-year Report
9th Feb 202411:19 amRNSNew ADVFN Italia website is launched
12th Jan 20242:00 pmRNSResult of Meeting
28th Dec 20231:10 pmRNSResult of AGM
21st Dec 20237:00 amRNSFinal Results
5th Dec 20234:00 pmRNSNotice of AGM
16th Nov 20231:30 pmRNSHolding(s) in Company
21st Sep 202312:00 pmRNSADFVN connects audience to Doceo content
15th Aug 20236:05 pmRNSCorporate update
9th Jun 20236:15 pmRNSDirector/PDMR Shareholding
2nd Jun 202312:14 pmRNSTrading and corporate update
16th May 20234:33 pmRNSHolding(s) in Company
5th May 20233:06 pmRNSTotal Voting Rights
4th Apr 20237:00 amRNSIssue of Equity
30th Mar 20232:07 pmRNSHolding(s) in Company
30th Mar 20232:05 pmRNSHolding(s) in Company
23rd Mar 20235:02 pmRNSHolding(s) in Company
23rd Mar 20235:01 pmRNSHolding(s) in Company
23rd Mar 20235:00 pmRNSHolding(s) in Company
23rd Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20236:20 pmRNSAdmission update
14th Mar 202312:05 pmRNSFurther equity issue under the Open Offer
6th Mar 20237:00 amRNSHalf-year Report
6th Feb 202311:53 amRNSDirectorate Change
13th Jan 202311:19 amRNSResult of AGM
11th Jan 20231:15 pmRNSHolding(s) in Company
11th Jan 202311:10 amRNSHolding(s) in Company
11th Jan 202311:10 amRNSHolding(s) in Company
11th Jan 202310:49 amRNSHolding(s) in Company
11th Jan 202310:49 amRNSHolding(s) in Company
10th Jan 20237:00 amRNSCorporate update
9th Jan 20235:22 pmRNSTotal voting rights, Director / PDMR shareholding
6th Jan 20232:04 pmRNSFinal Results of Open Offer
6th Jan 20237:00 amRNSResults of Open Offer
20th Dec 20227:00 amRNSOpen Offer timetable and AGM
6th Dec 20227:00 amRNSOpen Offer
6th Dec 20227:00 amRNSFinal Results
28th Nov 20227:00 amRNSCorporate update
15th Sep 202210:45 amRNSAppointment of joint corporate broker
19th Aug 20224:15 pmRNSCorporate update
8th Aug 20227:00 amRNSDirectorate Change
6th Jun 20227:00 amRNSTrading and Corporate Update
29th Apr 20222:05 pmRNSResult of Meeting
28th Apr 20224:41 pmRNSSecond Price Monitoring Extn
28th Apr 20224:35 pmRNSPrice Monitoring Extension
28th Apr 20222:01 pmRNSHolding(s) in Company
22nd Apr 20224:00 pmRNSTotal Voting Rights
20th Apr 202211:05 amRNSSecond Price Monitoring Extn
20th Apr 202211:00 amRNSPrice Monitoring Extension
13th Apr 20229:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.